Bendamustine and HDAC Inhibitor Combination Therapy for Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments with HDAC inhibitors face challenges in effectively inhibiting tumor growth and managing side effects such as thrombocytopenia, and there is a need for improved combinations of HDAC inhibitors with other chemotherapeutic agents to enhance therapeutic efficacy.
Innovation Solution
A combination of bendamustine and a histone deacetylase (HDAC) inhibitor, specifically N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide, is used in pharmaceutical compositions for treating various cancers, with different administration regimens including simultaneous, sequential, and staggered dosing, and in various solid dosage forms for oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HDAC inhibitors are used to inhibit tumor growth, then tumor growth inhibition is improved, but thrombocytopenia side effects worsen
Solution Approach 1:
The patent combines bendamustine and HDAC inhibitor in a single pharmaceutical composition for simultaneous administration, aiming to achieve synergistic anti-tumor effects while managing side effects through coordinated delivery of both agents
Solution Approach 2:
The patent employs specific dosing regimens (e.g., 90mg/m2 bendamustine on days 1 and 2, HDAC inhibitor 200mg orally days 1-5) and administration timing (simultaneous, sequential, or staggered) to optimize the balance between tumor growth inhibition and thrombocytopenia management
2Reliability
If HDAC inhibitors are administered to maintain effective plasma concentrations, then therapeutic effect is improved, but duration of treatment and side effects worsen
Solution Approach 1:
The patent employs cyclic dosing regimens with treatment phases (e.g., 5 days of HDAC inhibitor administration) followed by interruption periods (e.g., 2-7 days without treatment), creating periodic action patterns that maintain therapeutic efficacy while allowing recovery from side effects
Solution Approach 2:
The patent implements pre-medication with bendamustine before HDAC inhibitor administration in sequential regimens, and uses growth factor support (e.g., filgrastim) as preliminary protective action against anticipated thrombocytopenia
3Reliability
If combination therapy with bendamustine and HDAC inhibitor is used, then therapeutic efficacy is improved, but device complexity and dosing regimens worsen
Solution Approach 1:
The patent combines bendamustine and HDAC inhibitor in a single pharmaceutical composition for simultaneous administration, aiming to simplify the treatment process by delivering both agents together in one formulation rather than requiring separate administration procedures
Solution Approach 2:
The pharmaceutical composition serves multiple functions: delivering both bendamustine and HDAC inhibitor therapeutically, providing synergistic anti-tumor activity, and enabling flexible administration options (simultaneous, sequential, or staggered dosing) from a single formulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination effectively inhibits tumor growth, reduces the incidence of grade 4 thrombocytopenia, and maintains effective plasma concentrations of the HDAC inhibitor for extended periods, enhancing the therapeutic effect and minimizing side effects.
Implementation Method 1
Deacetylation of nucleosomal histones is catalyzed by a group of enzymes known as histone deacetylases (HDACs)
Implementation Method 2
The combination effectively inhibits tumor growth, reduces the incidence of grade 4 thrombocytopenia
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.